APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Antihemophilic Factor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Antihemophilic Factor Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchRecombinant Antihemophilic Factor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Antihemophilic Factor Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Recombinant Antihemophilic Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Antihemophilic Factor Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Antihemophilic Factor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Recombinant Antihemophilic Factor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Antihemophilic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Antihemophilic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Antihemophilic Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Antihemophilic Factor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Antihemophilic Factor market include Takeda, Sobi, Sanofi, Pfizer, Bayer, Octapharma, Novo Nordisk, CSL and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Antihemophilic Factor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Antihemophilic Factor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Antihemophilic Factor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Antihemophilic Factor market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Antihemophilic Factor Segment by Company

Takeda

Sobi

Sanofi

Pfizer

Bayer

Octapharma

Novo Nordisk

CSL

Biogen

Recombinant Antihemophilic Factor Segment by Type

200IU

250IU

Recombinant Antihemophilic Factor Segment by Application

Hospital

Pharmacy

Recombinant Antihemophilic Factor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Recombinant Antihemophilic Factor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Antihemophilic Factor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Antihemophilic Factor significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Antihemophilic Factor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antihemophilic Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antihemophilic Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antihemophilic Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Antihemophilic Factor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Antihemophilic Factor industry.

Chapter 3: Detailed analysis of Recombinant Antihemophilic Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Antihemophilic Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Antihemophilic Factor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Antihemophilic Factor Industry Trends Table 2. Recombinant Antihemophilic Factor Industry Drivers Table 3. Recombinant Antihemophilic Factor Industry Opportunities and Challenges Table 4. Recombinant Antihemophilic Factor Industry Restraints Table 5. Global Recombinant Antihemophilic Factor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Antihemophilic Factor Revenue Share by Company (2021-2026) Table 7. Global Recombinant Antihemophilic Factor Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Recombinant Antihemophilic Factor Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Antihemophilic Factor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Recombinant Antihemophilic Factor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Antihemophilic Factor Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Antihemophilic Factor Company, Product Type & Application Table 13. Global Recombinant Antihemophilic Factor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Antihemophilic Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 200IU Table 18. Significant Companies of 250IU Table 19. Global Recombinant Antihemophilic Factor Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Recombinant Antihemophilic Factor Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Recombinant Antihemophilic Factor Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Recombinant Antihemophilic Factor Sales Volume Share by Type (2021-2026) Table 23. Global Recombinant Antihemophilic Factor Sales Volume Share by Type (2027-2032) Table 24. Global Recombinant Antihemophilic Factor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Recombinant Antihemophilic Factor Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Recombinant Antihemophilic Factor Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Recombinant Antihemophilic Factor Sales Value Share by Type (2021-2026) Table 28. Global Recombinant Antihemophilic Factor Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Recombinant Antihemophilic Factor Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Recombinant Antihemophilic Factor Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Recombinant Antihemophilic Factor Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Recombinant Antihemophilic Factor Sales Volume Share by Application (2021-2026) Table 35. Global Recombinant Antihemophilic Factor Sales Volume Share by Application (2027-2032) Table 36. Global Recombinant Antihemophilic Factor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Recombinant Antihemophilic Factor Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Recombinant Antihemophilic Factor Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Recombinant Antihemophilic Factor Sales Value Share by Application (2021-2026) Table 40. Global Recombinant Antihemophilic Factor Sales Value Share by Application (2027-2032) Table 41. Global Recombinant Antihemophilic Factor Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Recombinant Antihemophilic Factor Sales by Region (2021-2026) & (W Units) Table 43. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2021-2026) Table 44. Global Recombinant Antihemophilic Factor Sales by Region (2027-2032) & (W Units) Table 45. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2027-2032) Table 46. Global Recombinant Antihemophilic Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Recombinant Antihemophilic Factor Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Recombinant Antihemophilic Factor Sales Value Share by Region (2021-2026) Table 49. Global Recombinant Antihemophilic Factor Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Recombinant Antihemophilic Factor Sales Value Share by Region (2027-2032) Table 51. Global Recombinant Antihemophilic Factor Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Recombinant Antihemophilic Factor Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Recombinant Antihemophilic Factor Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Recombinant Antihemophilic Factor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Recombinant Antihemophilic Factor Sales by Country (2021-2026) & (W Units) Table 56. Global Recombinant Antihemophilic Factor Sales Market Share by Country (2021-2026) Table 57. Global Recombinant Antihemophilic Factor Sales by Country (2027-2032) & (W Units) Table 58. Global Recombinant Antihemophilic Factor Sales Market Share by Country (2027-2032) Table 59. Global Recombinant Antihemophilic Factor Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Recombinant Antihemophilic Factor Sales Value Market Share by Country (2021-2026) Table 61. Global Recombinant Antihemophilic Factor Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Recombinant Antihemophilic Factor Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Takeda Recombinant Antihemophilic Factor Product Portfolio Table 67. Takeda Recent Development Table 68. Sobi Company Information Table 69. Sobi Business Overview Table 70. Sobi Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Sobi Recombinant Antihemophilic Factor Product Portfolio Table 72. Sobi Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Recombinant Antihemophilic Factor Product Portfolio Table 77. Sanofi Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Recombinant Antihemophilic Factor Product Portfolio Table 82. Pfizer Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Bayer Recombinant Antihemophilic Factor Product Portfolio Table 87. Bayer Recent Development Table 88. Octapharma Company Information Table 89. Octapharma Business Overview Table 90. Octapharma Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Octapharma Recombinant Antihemophilic Factor Product Portfolio Table 92. Octapharma Recent Development Table 93. Novo Nordisk Company Information Table 94. Novo Nordisk Business Overview Table 95. Novo Nordisk Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Novo Nordisk Recombinant Antihemophilic Factor Product Portfolio Table 97. Novo Nordisk Recent Development Table 98. CSL Company Information Table 99. CSL Business Overview Table 100. CSL Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. CSL Recombinant Antihemophilic Factor Product Portfolio Table 102. CSL Recent Development Table 103. Biogen Company Information Table 104. Biogen Business Overview Table 105. Biogen Recombinant Antihemophilic Factor Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Biogen Recombinant Antihemophilic Factor Product Portfolio Table 107. Biogen Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Recombinant Antihemophilic Factor Distributors List Table 111. Recombinant Antihemophilic Factor Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Recombinant Antihemophilic Factor Product Image Figure 2. Global Recombinant Antihemophilic Factor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Antihemophilic Factor Sales (2021-2032) & (W Units) Figure 5. Global Recombinant Antihemophilic Factor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Recombinant Antihemophilic Factor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 200IU Image Figure 10. 250IU Image Figure 11. Global Recombinant Antihemophilic Factor Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Recombinant Antihemophilic Factor Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Recombinant Antihemophilic Factor Sales Volume Share by Type (2021-2032) Figure 14. Global Recombinant Antihemophilic Factor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant Antihemophilic Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Antihemophilic Factor Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Recombinant Antihemophilic Factor Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Recombinant Antihemophilic Factor Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Recombinant Antihemophilic Factor Sales Volume Share by Application (2021-2032) Figure 22. Global Recombinant Antihemophilic Factor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Recombinant Antihemophilic Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Antihemophilic Factor Sales Value Share by Application (2021-2032) Figure 25. Global Recombinant Antihemophilic Factor Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Recombinant Antihemophilic Factor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Antihemophilic Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Recombinant Antihemophilic Factor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 30. North America Recombinant Antihemophilic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Recombinant Antihemophilic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Recombinant Antihemophilic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 36. South America Recombinant Antihemophilic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Recombinant Antihemophilic Factor Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Recombinant Antihemophilic Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Recombinant Antihemophilic Factor Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Recombinant Antihemophilic Factor Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 200IU
  • 250IU
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Takeda
  • Sobi
  • Sanofi
  • Pfizer
  • Bayer
  • Octapharma
  • Novo Nordisk
  • CSL
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Antihemophilic Factor Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Antihemophilic Factor Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Antihemophilic Factor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Antihemophilic Factor Market Dynamics
  1. 2.1 Recombinant Antihemophilic Factor Industry Trends
  2. 2.2 Recombinant Antihemophilic Factor Industry Drivers
  3. 2.3 Recombinant Antihemophilic Factor Industry Opportunities and Challenges
  4. 2.4 Recombinant Antihemophilic Factor Industry Restraints
3 Recombinant Antihemophilic Factor Market by Company
  1. 3.1 Global Recombinant Antihemophilic Factor Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Antihemophilic Factor Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Antihemophilic Factor Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Antihemophilic Factor Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Antihemophilic Factor Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Antihemophilic Factor Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Antihemophilic Factor Company Product Type and Application
  8. 3.8 Global Recombinant Antihemophilic Factor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Antihemophilic Factor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Antihemophilic Factor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Antihemophilic Factor Market by Type
  1. 4.1 Recombinant Antihemophilic Factor Type Introduction
  2. 4.1.1 200IU
  3. 4.1.2 250IU
  4. 4.2 Global Recombinant Antihemophilic Factor Sales Volume by Type
  5. 4.2.1 Global Recombinant Antihemophilic Factor Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Antihemophilic Factor Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Recombinant Antihemophilic Factor Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Recombinant Antihemophilic Factor Sales Value by Type
  9. 4.3.1 Global Recombinant Antihemophilic Factor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Antihemophilic Factor Sales Value by Type (2021-2032)
  11. 4.3.3 Global Recombinant Antihemophilic Factor Sales Value Share by Type (2021-2032)
5 Recombinant Antihemophilic Factor Market by Application
  1. 5.1 Recombinant Antihemophilic Factor Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Recombinant Antihemophilic Factor Sales Volume by Application
  5. 5.2.1 Global Recombinant Antihemophilic Factor Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Antihemophilic Factor Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Recombinant Antihemophilic Factor Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Recombinant Antihemophilic Factor Sales Value by Application
  9. 5.3.1 Global Recombinant Antihemophilic Factor Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Antihemophilic Factor Sales Value by Application (2021-2032)
  11. 5.3.3 Global Recombinant Antihemophilic Factor Sales Value Share by Application (2021-2032)
6 Recombinant Antihemophilic Factor Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Antihemophilic Factor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Antihemophilic Factor Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Antihemophilic Factor Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Antihemophilic Factor Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Antihemophilic Factor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Antihemophilic Factor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Antihemophilic Factor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Antihemophilic Factor Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Antihemophilic Factor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Antihemophilic Factor Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Antihemophilic Factor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Antihemophilic Factor Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Antihemophilic Factor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Antihemophilic Factor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Antihemophilic Factor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Antihemophilic Factor Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Antihemophilic Factor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Antihemophilic Factor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Antihemophilic Factor Sales Value Share by Country, 2025 VS 2032
7 Recombinant Antihemophilic Factor Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Antihemophilic Factor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Antihemophilic Factor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Antihemophilic Factor Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Antihemophilic Factor Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Antihemophilic Factor Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Antihemophilic Factor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Antihemophilic Factor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Antihemophilic Factor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Antihemophilic Factor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Antihemophilic Factor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Antihemophilic Factor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Recombinant Antihemophilic Factor Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sobi
  8. 8.2.1 Sobi Company Information
  9. 8.2.2 Sobi Business Overview
  10. 8.2.3 Sobi Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sobi Recombinant Antihemophilic Factor Product Portfolio
  12. 8.2.5 Sobi Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Recombinant Antihemophilic Factor Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Recombinant Antihemophilic Factor Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Recombinant Antihemophilic Factor Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Octapharma
  32. 8.6.1 Octapharma Company Information
  33. 8.6.2 Octapharma Business Overview
  34. 8.6.3 Octapharma Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Octapharma Recombinant Antihemophilic Factor Product Portfolio
  36. 8.6.5 Octapharma Recent Developments
  37. 8.7 Novo Nordisk
  38. 8.7.1 Novo Nordisk Company Information
  39. 8.7.2 Novo Nordisk Business Overview
  40. 8.7.3 Novo Nordisk Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novo Nordisk Recombinant Antihemophilic Factor Product Portfolio
  42. 8.7.5 Novo Nordisk Recent Developments
  43. 8.8 CSL
  44. 8.8.1 CSL Company Information
  45. 8.8.2 CSL Business Overview
  46. 8.8.3 CSL Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CSL Recombinant Antihemophilic Factor Product Portfolio
  48. 8.8.5 CSL Recent Developments
  49. 8.9 Biogen
  50. 8.9.1 Biogen Company Information
  51. 8.9.2 Biogen Business Overview
  52. 8.9.3 Biogen Recombinant Antihemophilic Factor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Biogen Recombinant Antihemophilic Factor Product Portfolio
  54. 8.9.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Antihemophilic Factor Value Chain Analysis
  2. 9.1.1 Recombinant Antihemophilic Factor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Antihemophilic Factor Sales Mode & Process
  6. 9.2 Recombinant Antihemophilic Factor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Antihemophilic Factor Distributors
  9. 9.2.3 Recombinant Antihemophilic Factor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst